Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Reviva Pharmaceuticals’ clinical-stage disclosures can feel like wading through lab notebooks—every 10-K footnote hides R&D spend, every 8-K may signal a trial milestone or stock offering. If you have ever Googled "Reviva Pharmaceuticals SEC filings explained simply" or asked, “How do I track Reviva Pharmaceuticals insider trading Form 4 transactions?” you know the challenge.
Stock Titan turns those 200-page reports into clear insights. Our AI reads each Reviva Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR, flags cash-runway changes, and links drug-trial updates from 8-K material events explained in plain English. Need real-time alerts? Get "Reviva Pharmaceuticals Form 4 insider transactions real-time" pushed to your dashboard so you never miss an executive stock sale or option exercise. For deeper dives, AI-powered summaries highlight risk-factor shifts, shelf-registration details, and dilution math—essential for understanding Reviva Pharmaceuticals earnings report filing analysis.
Whether you’re evaluating convertible notes in an S-1, checking a Reviva Pharmaceuticals proxy statement executive compensation table, or comparing segments across the "Reviva Pharmaceuticals annual report 10-K simplified," our platform streamlines the process:
- Monitor "Reviva Pharmaceuticals executive stock transactions Form 4" alongside price charts.
- Query clinical timelines directly inside each filing—understanding Reviva Pharmaceuticals SEC documents with AI.
- Export data from "Reviva Pharmaceuticals quarterly earnings report 10-Q filing" to model cash burn per Phase 3 milestone.
Stop skimming PDFs and start focusing on decisions. Stock Titan delivers every Reviva disclosure—from insider trades to pipeline breakthroughs—in a format built for biotech investors who value speed and clarity.
Reviva Pharmaceuticals (Nasdaq: RVPH) entered into a $10 million registered public offering of 20 million common shares paired with 20 million five-year Series C warrants and 20 million one-year Series D warrants, all priced at $0.50 per unit.
Net proceeds of roughly $9 million will fund R&D, working capital and general corporate purposes. The warrants are immediately exercisable at $0.50, include 4.99%/9.99% ownership caps and Black-Scholes cash-out rights on fundamental transactions. Closing is expected 27 Jun 2025, subject to customary conditions, and the company agreed to 60-day lock-up on most new issuances and a 12-month restriction on variable-rate financings.
- Placement Agent: A.G.P./Alliance Global Partners—7% cash fee on most proceeds.
- Registration: effective S-3 (No. 333-276848), prospectus supplement filed.
- Use of proceeds focused on pipeline advancement.
Reviva Pharmaceuticals has announced a public offering of 20,000,000 shares of common stock at $0.50 per share, along with Series C and Series D Common Warrants. The total offering value is $10 million, with expected net proceeds of $9.3 million before expenses.
Key offering details:
- Each share comes with two warrants: one Series C warrant (5-year term) and one Series D warrant (12-month term)
- Both warrant series have an exercise price of $0.50 per share
- A.G.P./Alliance Global Partners serving as sole Placement Agent, receiving 7% fee (3.5% for certain investors)
- No minimum offering requirement or escrow arrangement
- Expected closing date: June 27, 2025
The offering represents a significant discount to the last reported share price of $0.8049 on Nasdaq (RVPH). The company notes it is a "smaller reporting company" and warns investors of potential risks, including limited warrant liquidity as no trading market exists or is planned for the warrants.
Reviva Pharmaceuticals Holdings has announced a new securities offering including shares of common stock, Series C and D Common Warrants, and Pre-Funded Warrants. The offering includes:
- Common stock (at $0.8049 per share last trading price) with accompanying warrants
- Series C Common Warrants with 5-year expiration and immediate exercisability
- Series D Common Warrants with 12-month expiration and immediate exercisability
- Pre-Funded Warrants for investors who would exceed 4.99% (or 9.99%) ownership
Key Details: A.G.P./Alliance Global Partners is serving as sole Placement Agent, receiving a 7% fee (3.5% for certain investors). The offering has no minimum requirement and will terminate by June 2025 unless completed sooner. Trading under symbol RVPH on Nasdaq Capital Market, the company qualifies as a "smaller reporting company." Proceeds will be immediately available for company use, though total offering amount remains undetermined.
FAQ
What is the current stock price of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the market cap of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the core focus of Reviva Pharmaceuticals Holdings Inc?
Which therapeutic areas does the company target?
How does Reviva differentiate its drug development approach?
What are the key components of Reviva's pipeline?
How is the company positioned within the pharmaceutical industry?
What are some challenges faced by companies like Reviva in this sector?
